ID   GR-M
AC   CVCL_2451
SY   GRM
DR   CLO; CLO_0003564
DR   EFO; EFO_0006577
DR   CLDB; cl1513
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03472907
DR   BioSample; SAMN10988055
DR   CCLE; GRM_SKIN
DR   Cell_Model_Passport; SIDM00468
DR   Cosmic; 2163785
DR   DepMap; ACH-001072
DR   ECACC; 95032301
DR   ESTDAB; ESTDAB-036
DR   IARC_TP53; 21349
DR   PharmacoDB; GRM_412_2019
DR   Wikidata; Q54871656
RX   PubMed=7780963;
RX   PubMed=15592718;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   http://iclac.org/wp-content/uploads/Cross-Contaminations_v9_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a PSN1 derivative (PubMed=25877200). Originally thought to originate from the thorax of a 36 year old male melanoma patient with skin metastases.
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00538.
CC   HLA typing: A*24:02,24:02; B*52:01:01,52:01:01; C*12:02,12:02; DPB1*09:01; DQB1*06:02,06:01:01; DRB1*15:01 (PubMed=15592718).
CC   Sequence variation: Homozygous for CDKN2A deletion (from parent cell line).
CC   Sequence variation: Heterozygous for KRAS p.Gly12Arg (c.34G>C) (CCLE).
CC   Sequence variation: Homozygous for SMAD4 deletion (from parent cell line).
CC   Sequence variation: TP53 p.Lys132Gln (c.394A>C) (CCLE).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=83.55%; East Asian, South=15.04%; South Asian=1.41%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: ESTDAB; ESTDAB-036; probable.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10
ST   D16S539: 10,11
ST   D18S51: 21
ST   D21S11: 29,30
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 10
ST   D8S1179: 10,14
ST   FGA: 23
ST   Penta D: 9,12
ST   Penta E: 14,15
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C8294; Pancreatic adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1644 ! PSN1
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 19
//
RX   PubMed=7780963;
RA   Easty D.J., Guthrie B.A., Maung K., Farr C.J., Lindberg R.A.,
RA   Toso R.J., Herlyn M., Bennett D.C.;
RT   "Protein B61 as a new growth factor: expression of B61 and
RT   up-regulation of its receptor epithelial cell kinase during melanoma
RT   progression.";
RL   Cancer Res. 55:2528-2532(1995).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//